Biohit OyjLTS:0DRP -2.95%78 FCF Margin % is -2.41% as of Dec. 2025. GuruFocus rates LTS:0DRP with a GF Score™ of 78/100 and a GF Value™ of €2.69 (Fairly Valued). The stock has 4 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Biohit Oyj ranks worse than 66.26% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Biohit Oyj's Free Cash Flow for the
six
months ended in Dec. 2025 was €-0.20 Mil. Biohit Oyj's Revenue for the
six
months ended in Dec. 2025 was €8.30 Mil. Therefore, Biohit Oyj's FCF Margin % for the quarter that ended in Dec. 2025 was -2.41%.
The historical rank and industry rank for Biohit Oyj's FCF Margin % or its related term are showing as below:
LTS:0DRP'
s FCF Margin % Range Over the Past 10 Years
Min: -31.1 Med: -0.83 Max: 16.34
Current: -10.83
During the past 13 years, the highest FCF Margin % of Biohit Oyj was 16.34%. The lowest was -31.10%. And the median was -0.83%.
LTS:0DRP's FCF Margin % is ranked worse than 66.26% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.03
vs LTS:0DRP: -10.83
Biohit Oyj FCF Margin % Related Terms
Biohit Oyj FCF Margin % Historical Data
* Premium members only.
The historical data trend for Biohit Oyj's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DRP vs ABT, SYK, MDT: FCF Margin % Comparison
For the Medical Devices subindustry, Biohit Oyj's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biohit Oyj FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biohit Oyj's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Biohit Oyj's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biohit Oyj (LTS:0DRP) has a FCF Margin % of -2.41% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Biohit Oyj and its competitors. According to the industry distribution chart, Biohit Oyj ranks #540 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 66.3%.
Is Biohit Oyj's FCF Margin % too high?
Biohit Oyj's current FCF Margin % is -2.41%. Based on the distribution chart, Biohit Oyj ranks #540 out of 815 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Biohit Oyj has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biohit Oyj's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Biohit Oyj ranks #540 out of 815 companies for FCF Margin %. This places Biohit Oyj in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Biohit Oyj and its competitors. Biohit Oyj's current FCF Margin % is -2.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biohit Oyj stock overvalued right now?
Based on GuruFocus' analysis, Biohit Oyj (LTS:0DRP) is currently considered Fairly Valued. The stock's GF Value™ is €2.69, compared to a current price of €2.47 — trading 8.4% below its estimated fair value. The current FCF Margin % is -2.41%. Biohit Oyj's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Biohit Oyj (LTS:0DRP), the current FCF Margin % is -2.41% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biohit Oyj (LTS:0DRP) Overvalued in 2026?
Based on GuruFocus' analysis, Biohit Oyj stock appears to be undervalued.
The current stock price of €2.47 is trading 8.4% below its estimated GF Value™ of €2.69.
GuruFocus considers Biohit Oyj to be Fairly Valued.
Key valuation signals for LTS:0DRP:
FCF Margin %: -2.41%
GF Value™: €2.69 vs. price of €2.47 (8.4% below fair value)
No single metric tells the full story. See the LTS:0DRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
78GF Score
Get the complete analysis for LTS:0DRP
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRP has been successfully added to your 
